Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Sep 21, 2013; 19(35): 5910-5916
Published online Sep 21, 2013. doi: 10.3748/wjg.v19.i35.5910
Published online Sep 21, 2013. doi: 10.3748/wjg.v19.i35.5910
A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma
Yi-Fu He, Chu-Shu Ji, Bing Hu, Chang-Lu Hu, Feng-Shou Jiang, Jian Chen, Yi-Wei Yao, Wei Wang, Department of Medical Oncology, Anhui Provincial Hospital affliated to Anhui Medical University, Hefei 230001, Anhui Province, China
Ping-Sheng Fan, Lei Zhu, Department of Medical Oncology, Anhui Provincial Cancer Hospital, Hefei 230031, Anhui Province, China
Author contributions: He YF, Ji CS, Fan PS, Hu CL, Chen J, Zhu L and Yao YW performed the majority of experiments; Jiang FS and Wang W provided analytical tools and were also involved in editing the manuscript; Hu B designed the study and provided financial support for this work; He YF and Hu B wrote the manuscript.
Supported by Natural Science Foundation of Anhui Province No. 070413256X; and Medical Research Foundation of Anhui Provincial Health Department No. 2010B001 and No. 13zc012
Correspondence to: Bing Hu, Professor, Department of Medical Oncology, Anhui Provincial Hospital affliated to Anhui Medical University, 17 Lujiang Road , Hefei 230001, Anhui Province, China. hubing3756@hotmail.com
Telephone: +86-551-62283337 Fax: +86-551-62283864
Received: June 2, 2013
Revised: August 1, 2013
Accepted: August 12, 2013
Published online: September 21, 2013
Processing time: 110 Days and 14.3 Hours
Revised: August 1, 2013
Accepted: August 12, 2013
Published online: September 21, 2013
Processing time: 110 Days and 14.3 Hours
Core Tip
Core tip: Esophageal cancers are among the most aggressive tumors with a poor prognosis. Till now, there has been no standard chemotherapy regimen for advanced esophageal cancer. In this paper, we conducted a phase II study on combination chemotherapy consisting of paclitaxel and nedaplatin in previously untreated patients with metastatic esophageal squamous cell carcinoma (ESCC). Our results demonstrated that the combination of two drugs is active and well tolerated as a first-line therapy for patients with recurrent or metastatic ESCC.